Dubrofsky Lisa, Kerzner Ryan S, Delaunay Chloë, Kolenda Camille, Pepin Jocelyne, Schwartz Blair C
MDCM, is an Internal Medicine Resident with the Department of Medicine, McGill University, Montréal, Quebec.
BPharm, MSc, is an Antimicrobial Stewardship Pharmacist with the Department of Pharmacy, Sir Mortimer B Davis Jewish General Hospital, Montréal, Quebec.
Can J Hosp Pharm. 2016 Jan-Feb;69(1):7-13. doi: 10.4212/cjhp.v69i1.1517.
Intravenous (IV) hydration is considered a protective factor in reducing the incidence of acyclovir-induced nephrotoxicity. A systems-based review of cases of acyclovir-associated acute kidney injury can be used to examine institution-, care provider-, and task-related factors involved in administering the drug and can serve as a basis for developing a quality improvement intervention to achieve safer administration of acyclovir.
To explore the effectiveness of the study institution's inter-disciplinary quality improvement intervention in increasing the dilution of acyclovir before IV administration.
After conducting a systems-based review for intervention development, a retrospective analysis was undertaken to compare IV administration of acyclovir in the 6-month periods before and after implementation of the intervention. The study population was a sequential sample of all patients over 18 years of age who were seen in the emergency department or admitted to a ward and who received at least one IV dose of acyclovir at the study institution. The primary outcome was the volume in which each acyclovir dose was delivered. The secondary outcomes were the hourly rate of fluid administration, the frequency of an increase in hourly hydration rate, and the incidence of acute kidney injury.
Eighty-four patients (44 in the pre-intervention period and 40 in the post-intervention period) received IV acyclovir and had evaluable data for the primary outcome. The median volume in which the acyclovir dose was administered was significantly higher in the post-intervention group (250 mL versus 100 mL, p < 0.001).
In this study, an easily implemented intervention significantly increased the volume of IV fluid administered to patients receiving acyclovir. Adequately powered prospective studies are suggested to investigate the effectiveness of this intervention on the clinically relevant incidence of acyclovir-induced nephrotoxicity.
静脉补液被认为是降低阿昔洛韦诱导的肾毒性发生率的保护因素。对阿昔洛韦相关性急性肾损伤病例进行基于系统的回顾,可用于检查给药过程中涉及的机构、医护人员和任务相关因素,并可为制定质量改进干预措施提供依据,以实现更安全地使用阿昔洛韦。
探讨研究机构的跨学科质量改进干预措施在增加阿昔洛韦静脉给药前稀释度方面的有效性。
在基于系统的回顾以制定干预措施之后,进行回顾性分析,比较干预措施实施前后6个月内阿昔洛韦的静脉给药情况。研究人群为在急诊科就诊或入住病房且在研究机构接受至少一剂阿昔洛韦静脉给药的所有18岁以上患者的连续样本。主要结局是每次阿昔洛韦给药的液体量。次要结局是每小时补液速度、每小时补液速度增加的频率以及急性肾损伤的发生率。
84例患者(干预前44例,干预后40例)接受了阿昔洛韦静脉给药,并具有可用于主要结局评估的数据。干预后组中阿昔洛韦给药的中位数液体量显著更高(250 mL对100 mL,p < 0.001)。
在本研究中,一项易于实施的干预措施显著增加了接受阿昔洛韦治疗患者的静脉补液量。建议开展有足够样本量的前瞻性研究,以调查该干预措施对阿昔洛韦诱导的肾毒性临床相关发生率的有效性。